资讯

Incyclix Bio Granted U.S. FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified ...
Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic ...
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical ...
Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...